DK1404377T3 - Forbedrede chelatorkonjugater - Google Patents

Forbedrede chelatorkonjugater

Info

Publication number
DK1404377T3
DK1404377T3 DK02745600T DK02745600T DK1404377T3 DK 1404377 T3 DK1404377 T3 DK 1404377T3 DK 02745600 T DK02745600 T DK 02745600T DK 02745600 T DK02745600 T DK 02745600T DK 1404377 T3 DK1404377 T3 DK 1404377T3
Authority
DK
Denmark
Prior art keywords
chelator conjugates
improved
improved chelator
radiometal
conjugates
Prior art date
Application number
DK02745600T
Other languages
English (en)
Inventor
Torgrim Engell
Colin Mill Archer
Harry John Wadsworth
Original Assignee
Ge Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ge Healthcare Ltd filed Critical Ge Healthcare Ltd
Application granted granted Critical
Publication of DK1404377T3 publication Critical patent/DK1404377T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/32Oximes
    • C07C251/34Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C251/36Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with the carbon atoms of the oxyimino groups bound to hydrogen atoms or to acyclic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/0002General or multifunctional contrast agents, e.g. chelated agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745Blood coagulation or fibrinolysis factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Optics & Photonics (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
DK02745600T 2001-07-10 2002-07-10 Forbedrede chelatorkonjugater DK1404377T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0116815.2A GB0116815D0 (en) 2001-07-10 2001-07-10 Improved chelator conjugates

Publications (1)

Publication Number Publication Date
DK1404377T3 true DK1404377T3 (da) 2006-01-30

Family

ID=9918227

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02745600T DK1404377T3 (da) 2001-07-10 2002-07-10 Forbedrede chelatorkonjugater

Country Status (20)

Country Link
US (2) US7597875B2 (da)
EP (1) EP1404377B1 (da)
JP (1) JP5015409B2 (da)
KR (1) KR100892009B1 (da)
CN (4) CN101538313A (da)
AT (1) ATE304866T1 (da)
AU (1) AU2002317317B2 (da)
BR (1) BR0210965A (da)
CA (1) CA2450690C (da)
DE (1) DE60206272T2 (da)
DK (1) DK1404377T3 (da)
ES (1) ES2250671T3 (da)
GB (1) GB0116815D0 (da)
HU (1) HU228850B1 (da)
IL (1) IL159388A0 (da)
MX (1) MXPA04000210A (da)
NO (1) NO334093B1 (da)
RU (1) RU2298012C2 (da)
WO (1) WO2003006070A2 (da)
ZA (1) ZA200400143B (da)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6972122B2 (en) * 2001-01-05 2005-12-06 Duke University Contrast enhancement agent for magnetic resonance imaging
WO2003006491A2 (en) * 2001-07-10 2003-01-23 Amersham Health As Peptide-based compounds for targeting intergin receptors
NO20030115D0 (no) 2003-01-09 2003-01-09 Amersham Health As Kontrastmiddel
EP1699495A2 (en) 2003-11-06 2006-09-13 Amersham Health AS Conjugates of angiotensin ii and an imaging moiety
GB0416062D0 (en) * 2004-07-19 2004-08-18 Amersham Plc Improved N4 chelator conjugates
JP2007512321A (ja) * 2003-11-24 2007-05-17 ジーイー・ヘルスケア・アクスイェ・セルスカプ 造影剤
JP2007526300A (ja) * 2004-03-04 2007-09-13 ジーイー・ヘルスケア・アクスイェ・セルスカプ 医薬化合物
ES2358745T3 (es) 2004-11-22 2011-05-13 Ge Healthcare As Agentes de contraste para señalar matriz extracelular.
GB0427392D0 (en) * 2004-12-15 2005-01-19 Amersham Plc Stabilised 99mTc compositions
WO2006131803A2 (en) * 2005-06-08 2006-12-14 Ge Healthcare Limited Method for the use of [11c] carbon monoxide in labeling synthesis of 11c-labelled esters and acids by sensitized photo-induced free radical carbonylation
GB0515974D0 (en) * 2005-08-03 2005-09-07 Ge Healthcare Ltd Compounds and imaging methods
WO2007094683A1 (en) 2006-02-15 2007-08-23 Ge Healthcare As Contrast agents
US7943117B2 (en) * 2006-06-08 2011-05-17 Atomic Energy Council—Institute of Nuclear Research Method for testing radiochemical purity of Tc-99m-TRODAT-1
KR20090097868A (ko) * 2006-12-11 2009-09-16 지이 헬스케어 에이에스 방사선 표지된 펩티드 기재 화합물 및 그의 용도
US9701694B2 (en) 2008-12-02 2017-07-11 The University Of Melbourne Nitrogen-containing macrocyclic conjugates as radiopharmaceuticals
GB0922014D0 (en) 2009-12-17 2010-02-03 Ge Healthcare Ltd Novel integrin binders
EP2598175B1 (en) * 2010-07-27 2020-05-20 Serac Healthcare Limited Radiopharmaceutical compositions
GB201103696D0 (en) 2011-03-04 2011-04-20 Ge Healthcare Ltd Technetium labelled peptides
GB201110767D0 (en) 2011-06-24 2011-08-10 Ge Healthcare Ltd Infection imaging
US20130195756A1 (en) 2012-01-31 2013-08-01 General Electric Company 99mTc IMAGING AGENTS AND METHODS OF USE
JP2016510342A (ja) * 2013-02-15 2016-04-07 トーマス・ジェファーソン・ユニバーシティThomas Jefferson University 腫瘍画像化のためのキット
GB201314936D0 (en) 2013-08-21 2013-10-02 Ge Healthcare Ltd Radiolabelling method
GB201322456D0 (en) 2013-12-18 2014-02-05 Ge Healthcare Ltd Radiotracer compositions and methods
EP3131585B1 (en) 2014-03-19 2020-07-15 Universität Zürich Multidentate bifunctional chelating agents for radionuclide complexation in diagnostics and therapy
WO2019217571A1 (en) * 2018-05-08 2019-11-14 University Of Miami Materials and methods for the delivery of therapeutic nucleic acids to tissues
EP3793619A4 (en) 2018-05-16 2022-01-12 Emory University Styrylbenzothiazole derivatives and uses in imaging
CN111548275A (zh) * 2020-05-27 2020-08-18 龙曦宁(上海)医药科技有限公司 一种2-(氨基甲基)-n1,n1-二甲基丙烷-1,3-二胺三盐酸盐的合成方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1588978A (en) * 1977-07-19 1981-05-07 Ici Ltd Coating processes
DE3930674A1 (de) * 1989-09-11 1991-03-21 Diagnostikforschung Inst Bifunktionelle chelatbildner zur komplexierung von tc- und re-isotopen, verfahren zu ihrer herstellung und darstellung von konjugaten daraus sowie deren verwendung in diagnostik und therapie
US5849261A (en) * 1991-02-08 1998-12-15 Diatide, Inc. Radiolabeled vasoactive intestinal peptides for diagnosis and therapy
US5808091A (en) * 1991-10-29 1998-09-15 Bracco International B.V. Rhenium and technetium complexes containing a hypoxia localizing moiety
CA2168652A1 (en) * 1993-08-04 1995-02-16 Colin Mill Archer Radiometal complexes that localise in hypoxic tissue
WO1995019187A1 (en) * 1994-01-12 1995-07-20 Amersham International Plc Biological targeting agents
CA2156605A1 (en) * 1994-01-12 1995-07-20 Bracco International B.V. Ligands and metal complexes thereof
IL139385A (en) 1998-05-15 2005-09-25 Amersham Plc Labelled glutamine and lysine analogues, metal complexes thereof, and uses thereof for diagnosis
US6783711B2 (en) * 2000-05-23 2004-08-31 Ge Osmonics, Inc. Process for preparing a sulfonamide polymer matrix
WO2002072718A1 (en) * 2001-03-08 2002-09-19 Matsushita Electric Industrial Co., Ltd. Inkjet recording ink, method for producing said ink, and ink cartridge and recording device having said ink

Also Published As

Publication number Publication date
NO334093B1 (no) 2013-12-09
US20100040542A1 (en) 2010-02-18
MXPA04000210A (es) 2004-07-23
WO2003006070A2 (en) 2003-01-23
AU2002317317B2 (en) 2005-11-17
CA2450690A1 (en) 2003-01-23
JP2005500325A (ja) 2005-01-06
BR0210965A (pt) 2004-06-08
IL159388A0 (en) 2004-06-01
CN101537190A (zh) 2009-09-23
ATE304866T1 (de) 2005-10-15
HUP0401265A2 (hu) 2004-09-28
KR100892009B1 (ko) 2009-04-07
CN101538313A (zh) 2009-09-23
KR20040017287A (ko) 2004-02-26
EP1404377A2 (en) 2004-04-07
US7597875B2 (en) 2009-10-06
WO2003006070A3 (en) 2003-08-21
CN100509061C (zh) 2009-07-08
GB0116815D0 (en) 2001-08-29
DE60206272T2 (de) 2006-07-13
HU228850B1 (en) 2013-06-28
CN101607913A (zh) 2009-12-23
NO20035597D0 (no) 2003-12-16
NO20035597L (no) 2004-03-03
EP1404377B1 (en) 2005-09-21
HUP0401265A3 (en) 2005-11-28
JP5015409B2 (ja) 2012-08-29
HK1064585A1 (en) 2005-02-04
US8852550B2 (en) 2014-10-07
RU2003137592A (ru) 2005-05-20
CA2450690C (en) 2009-03-24
CN101607913B (zh) 2012-07-04
US20040258619A1 (en) 2004-12-23
ZA200400143B (en) 2004-12-29
CN1527727A (zh) 2004-09-08
RU2298012C2 (ru) 2007-04-27
DE60206272D1 (de) 2005-10-27
ES2250671T3 (es) 2006-04-16

Similar Documents

Publication Publication Date Title
DK1404377T3 (da) Forbedrede chelatorkonjugater
MA30153B1 (fr) Anticorps anti-ox40l et methodes correspondantes
DE60230890D1 (de) Indolizine als kinaseproteinhemmer
ECSP034600A (es) Compuestos de lactama
IL181529A (en) A method for radiofluorination, a compound containing radioactive fluorine and its use in the preparation of a radioactive drug
DE50202328D1 (de) Amidofunktionelle aminopolydiorganosiloxane
BRPI0307702B8 (pt) formulações de solução contendo anticorpo
CL2013002895A1 (es) Compuestos derivados de 7,8-dihidro-5h-pteridin-6-ona, utiles como intermediarios en la sintesis de compuestos derivados de pteridinona (divisional de la solicitud 3123-2005).
MA30042B1 (fr) Composes calcilytiques
TR200003389T2 (tr) 2-(2-klorofenil)-3,4-dihidro-2H-pirol türevleri.
DE60124296D1 (de) Biphenylcarbonsäureamide, die sich als lipidsenker eignen
DE60210598D1 (de) 3,7-DIAZABICYCLOc3.3.1Ü-FORMULIERUNGEN ALS ANTIARRHYTHMIKA
TW200716605A (en) 2,6-quinolinyl derivatives, processes for preparing them and their uses
TR199901017A2 (xx) B�cek ilac� terkibi.
EA200401289A1 (ru) Новые противоинфекционные соединения, способы их получения и фармацевтические композиции, содержащие эти соединения
DE60322562D1 (de) Konjugate von tc komplexen und zielgerichtete einheiten und ihre verwendung in nmr-diagnostik
DE60213084D1 (de) 3,7-DIAZABICYCLOc3.3.1Ü-FORMULIERUNGEN ALS ANTIARRHYTHMIKA
ID27733A (id) Metoksiminofenilasetamida
DE60330629D1 (de) Ether von 2,2,4-Trimethylpentane-1,3-Diolen als Duftstoff
NO20021429L (no) 1,4-dioksacykloalkan-2-oner og 1,4-dioksacykloalken-2-oner
EA200400764A1 (ru) 1,3-диарилпроп-2-ен-1-оны, композиция на их основе и применение
ITMI20030827A1 (it) Composizione farmaceutica contenente l'associazione levodopa/carbidopa.
BR0212397A (pt) Sìntese de glicosìdeos de solano
ES2183543T3 (es) Derivado de tiocolchicosida, su preparacion y su aplicacion en terapeutica.
HN1999000157A (es) 1,2,3 tetrahidroquinolinas 2 - sustituidas 4 - amino sustituidas.